Overview
Revelation Biosciences Q3 net loss narrows to $1.9 mln from $2.2 mln in 2024
Company's cash and equivalents rise to $12.7 mln from $6.5 mln at end of 2024
Outlook
Revelation expects to fund operations through Q3 2026
Result Drivers
CASH INFLOW - Gross proceeds of $9.6 mln from warrant inducement in September 2025 contributed to increased cash reserves
CASH POSITION - Cash and equivalents increased to $12.7 mln, primarily due to public offering and warrant inducement, offset by operating expenses
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$1.77
Q3 Net Income
-$1.90 mln
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Revelation Biosciences Inc is $21.25, about 94.9% above its November 5 closing price of $1.08
Press Release: ID:nACSWJDS8a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
